Liberum Capital reissued their buy rating on shares of AstraZeneca plc (LON:AZN) in a research report report published on Wednesday morning. The firm currently has a GBX 5,100 ($62.99) target price on the biopharmaceutical company’s stock.
A number of other brokerages have also commented on AZN. BNP Paribas reiterated a neutral rating and set a GBX 5,100 ($62.99) price target on shares of AstraZeneca plc in a report on Sunday, January 15th. Investec started coverage on AstraZeneca plc in a report on Monday, January 23rd. They set a hold rating and a GBX 4,600 ($56.81) price target on the stock. Goldman Sachs Group Inc set a GBX 3,900 ($48.17) price target on AstraZeneca plc and gave the stock a sell rating in a report on Friday, February 17th. Deutsche Bank AG reiterated a buy rating and set a GBX 6,000 ($74.10) price target on shares of AstraZeneca plc in a report on Tuesday, December 13th. Finally, JPMorgan Chase & Co. reiterated a neutral rating and set a GBX 4,600 ($56.81) price target on shares of AstraZeneca plc in a report on Tuesday, December 6th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. AstraZeneca plc presently has a consensus rating of Hold and a consensus target price of GBX 5,018.36 ($61.98).
Shares of AstraZeneca plc (LON:AZN) opened at 4876.50 on Wednesday. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The stock’s 50 day moving average price is GBX 4,617.49 and its 200-day moving average price is GBX 4,602.58. The company’s market capitalization is GBX 61.70 billion.
Your IP Address:
The firm also recently announced a dividend, which was paid on Monday, March 20th. Investors of record on Thursday, February 16th were given a dividend of GBX 150.20 ($1.86) per share. This represents a yield of 3.52%. This is a boost from AstraZeneca plc’s previous dividend of $68.70. The ex-dividend date was Thursday, February 16th.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.